Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Romiplostim in Children and Young Adults With Severe Aplastic Anemia
NCT07001254Phase 2Withdrawn
- Start
- Apr 2025
- Primary completion
- Dec 2031
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label trial of romiplostim in aplastic anemia (2 cohorts). Primary endpoint: Hematologic Complete Response Rate at 24 weeks. Planned start Apr 2025; status: withdrawn.
02
Drugs
romiplostim
03
Conditions
aplastic anemia
Beyond the preview
Go deeper on NCT07001254.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07001254.